Miruna Sasu, PhD, MBA, president and CEO of COTA Healthcare, delves into how real-world data and evidence generation have changed, both within the past year and since the beginning of the COVID-19 pandemic.
Miruna Sasu, PhD, MBA, president and CEO of COTA Healthcare, delves into how real-world data and evidence generation have changed, both within the past year and since the beginning of the COVID-19 pandemic; in particular, how the more widespread use of virtual care has transformed the collection and handling of electronic data.
Transcript
Since you joined COTA, how has the field of real-world data and real-world evidence changed?
I joined COTA about a year ago in the role of chief strategy officer. A lot has changed over the past year. In fact, a lot has changed since the pandemic hit. One of the things that I would say on the on the user side and on this sort of, me trying to push things out there to make it easier for the patient and for the doctors that are treating patients, just introducing the virtual components of care has made a big difference in how we treat data and the importance of data. And so, on the COTA side, we breathe and live data every day. The idea for us is to be able to understand patients and the patient population to figure out what works and what doesn't work, and what can extend lives and what can make quality of life better.
Over the past year, I think that the environment has changed—the ecosystem has changed. The FDA has issued some guidance around how to handle electronic medical records, data, and evidence. And, of course, here at COTA, a lot has changed as well. We have a new strategy in place. We are working very closely with life science companies to perform external control arms on clinical trials using data, and we're seeing a big uptake of that in the past 12 to 18 months.
We also have large growing data sets, whereby companies can license those data sets. Those data sets can either be used for evidence generation or they can be used for training algorithms, for example. We've seen a lot of companies come up with predictive algorithms looking at predictability of care, predictability of outcomes, especially in oncology patients. Also, mobility: How are patients going to be moving from place to place in the post-COVID era? Are patients willing to continue to travel to, for example, a clinical trial site? In some cases, the answer to that is increasingly, “No,” because now they have video options and care options that are administered right at home.
And so, a lot has changed—the environment has changed, the ecosystem has changed, and COTA’s strategy has changed as well. We are making a big push on diversity and being sure that our data sets are representative of a diverse population and the epidemiologically relevant population in the United States.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More